Cronos Selling And Marketing Expenses vs Research Development Analysis

CRON Stock

CAD 2.83 0.06 2.08%

Cronos financial indicator trend analysis is way more than just evaluating Cronos Group prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cronos Group is a good investment. Please check the relationship between Cronos Selling And Marketing Expenses and its Research Development accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling And Marketing Expenses vs Research Development

Selling And Marketing Expenses vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cronos Group Selling And Marketing Expenses account and Research Development. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cronos' Selling And Marketing Expenses and Research Development is 0.93. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Research Development in the same time period over historical financial statements of Cronos Group, assuming nothing else is changed. The correlation between historical values of Cronos' Selling And Marketing Expenses and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Cronos Group are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Selling And Marketing Expenses i.e., Cronos' Selling And Marketing Expenses and Research Development go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Selling And Marketing Expenses

Research Development

Most indicators from Cronos' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cronos Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 11th of January 2025, Selling General Administrative is likely to drop to about 43.8 M. In addition to that, Tax Provision is likely to grow to about (3.5 M)

Cronos fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Long Term Debt Total	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Net Receivables	Good Will	Common Stock Total Equity
Total Assets		0.76	0.84	1.0	-0.99	0.98	0.93	1.0	0.97	1.0	0.89	0.84	0.92	0.74	0.85	1.0	0.4	0.81	0.98	0.83	0.88	0.58	0.74	0.76	0.7	0.89
Other Current Liab	0.76		0.98	0.71	-0.73	0.84	0.89	0.73	0.84	0.74	0.46	0.72	0.68	0.22	0.98	0.73	0.4	0.57	0.64	0.8	0.43	0.65	0.75	0.21	0.98	0.46
Total Current Liabilities	0.84	0.98		0.8	-0.82	0.9	0.94	0.81	0.89	0.82	0.57	0.76	0.78	0.38	1.0	0.81	0.39	0.64	0.73	0.84	0.58	0.67	0.73	0.37	0.94	0.6
Total Stockholder Equity	1.0	0.71	0.8		-0.99	0.97	0.9	1.0	0.95	1.0	0.92	0.82	0.91	0.77	0.8	1.0	0.39	0.82	0.99	0.81	0.9	0.56	0.73	0.79	0.65	0.91
Net Debt	-0.99	-0.73	-0.82	-0.99		-0.98	-0.91	-0.99	-0.95	-0.99	-0.87	-0.84	-0.92	-0.76	-0.83	-0.99	-0.35	-0.79	-0.97	-0.8	-0.9	-0.57	-0.74	-0.78	-0.67	-0.91
Retained Earnings	0.98	0.84	0.9	0.97	-0.98		0.94	0.97	0.98	0.97	0.8	0.86	0.89	0.63	0.91	0.97	0.38	0.77	0.94	0.84	0.81	0.63	0.82	0.66	0.81	0.82
Accounts Payable	0.93	0.89	0.94	0.9	-0.91	0.94		0.91	0.91	0.92	0.77	0.79	0.84	0.58	0.94	0.92	0.37	0.72	0.87	0.81	0.75	0.63	0.67	0.58	0.82	0.76
Cash	1.0	0.73	0.81	1.0	-0.99	0.97	0.91		0.95	1.0	0.9	0.82	0.92	0.75	0.82	1.0	0.36	0.79	0.99	0.79	0.89	0.56	0.74	0.77	0.67	0.9
Non Current Assets Total	0.97	0.84	0.89	0.95	-0.95	0.98	0.91	0.95		0.95	0.82	0.91	0.92	0.64	0.9	0.95	0.55	0.85	0.92	0.93	0.78	0.67	0.81	0.65	0.8	0.82
Cash And Short Term Investments	1.0	0.74	0.82	1.0	-0.99	0.97	0.92	1.0	0.95		0.9	0.8	0.9	0.75	0.83	1.0	0.34	0.79	0.99	0.79	0.89	0.55	0.72	0.77	0.68	0.9
Common Stock Shares Outstanding	0.89	0.46	0.57	0.92	-0.87	0.8	0.77	0.9	0.82	0.9		0.73	0.87	0.87	0.58	0.9	0.48	0.85	0.94	0.72	0.9	0.46	0.5	0.88	0.38	0.93
Non Current Liabilities Total	0.84	0.72	0.76	0.82	-0.84	0.86	0.79	0.82	0.91	0.8	0.73		0.85	0.5	0.78	0.8	0.7	0.85	0.79	0.87	0.64	0.68	0.88	0.55	0.69	0.7
Other Current Assets	0.92	0.68	0.78	0.91	-0.92	0.89	0.84	0.92	0.92	0.9	0.87	0.85		0.7	0.79	0.91	0.54	0.82	0.9	0.83	0.81	0.75	0.65	0.7	0.62	0.85
Other Stockholder Equity	0.74	0.22	0.38	0.77	-0.76	0.63	0.58	0.75	0.64	0.75	0.87	0.5	0.7		0.39	0.76	0.19	0.68	0.81	0.54	0.96	0.21	0.24	0.99	0.15	0.96
Total Liab	0.85	0.98	1.0	0.8	-0.83	0.91	0.94	0.82	0.9	0.83	0.58	0.78	0.79	0.39		0.82	0.41	0.66	0.74	0.85	0.58	0.68	0.74	0.38	0.94	0.61
Total Current Assets	1.0	0.73	0.81	1.0	-0.99	0.97	0.92	1.0	0.95	1.0	0.9	0.8	0.91	0.76	0.82		0.35	0.79	0.99	0.79	0.9	0.55	0.71	0.78	0.67	0.91
Short Long Term Debt Total	0.4	0.4	0.39	0.39	-0.35	0.38	0.37	0.36	0.55	0.34	0.48	0.7	0.54	0.19	0.41	0.35		0.72	0.37	0.74	0.2	0.45	0.5	0.2	0.34	0.33
Other Liab	0.81	0.57	0.64	0.82	-0.79	0.77	0.72	0.79	0.85	0.79	0.85	0.85	0.82	0.68	0.66	0.79	0.72		0.81	0.85	0.73	0.49	0.65	0.69	0.5	0.79
Net Tangible Assets	0.98	0.64	0.73	0.99	-0.97	0.94	0.87	0.99	0.92	0.99	0.94	0.79	0.9	0.81	0.74	0.99	0.37	0.81		0.76	0.92	0.5	0.68	0.84	0.57	0.93
Property Plant And Equipment Net	0.83	0.8	0.84	0.81	-0.8	0.84	0.81	0.79	0.93	0.79	0.72	0.87	0.83	0.54	0.85	0.79	0.74	0.85	0.76		0.63	0.65	0.72	0.52	0.77	0.7
Current Deferred Revenue	0.88	0.43	0.58	0.9	-0.9	0.81	0.75	0.89	0.78	0.89	0.9	0.64	0.81	0.96	0.58	0.9	0.2	0.73	0.92	0.63		0.34	0.45	0.97	0.36	0.99
Non Currrent Assets Other	0.58	0.65	0.67	0.56	-0.57	0.63	0.63	0.56	0.67	0.55	0.46	0.68	0.75	0.21	0.68	0.55	0.45	0.49	0.5	0.65	0.34		0.5	0.19	0.69	0.37
Other Assets	0.74	0.75	0.73	0.73	-0.74	0.82	0.67	0.74	0.81	0.72	0.5	0.88	0.65	0.24	0.74	0.71	0.5	0.65	0.68	0.72	0.45	0.5		0.32	0.74	0.48
Net Receivables	0.76	0.21	0.37	0.79	-0.78	0.66	0.58	0.77	0.65	0.77	0.88	0.55	0.7	0.99	0.38	0.78	0.2	0.69	0.84	0.52	0.97	0.19	0.32		0.14	0.96
Good Will	0.7	0.98	0.94	0.65	-0.67	0.81	0.82	0.67	0.8	0.68	0.38	0.69	0.62	0.15	0.94	0.67	0.34	0.5	0.57	0.77	0.36	0.69	0.74	0.14		0.38
Common Stock Total Equity	0.89	0.46	0.6	0.91	-0.91	0.82	0.76	0.9	0.82	0.9	0.93	0.7	0.85	0.96	0.61	0.91	0.33	0.79	0.93	0.7	0.99	0.37	0.48	0.96	0.38

Click cells to compare fundamentals

Cronos Account Relationship Matchups

Cronos fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.9B	1.4B	1.2B	1.1B	1.3B	809.1M
Other Current Liab	183.3M	37.1M	18.5M	16.5M	19.0M	18.0M
Total Current Liabilities	206.8M	54.4M	68.1M	41.4M	47.6M	75.2M
Total Stockholder Equity	1.7B	1.3B	1.1B	1.1B	1.3B	730.8M
Net Debt	(1.1B)	(877.2M)	(760.8M)	(666.7M)	(600.1M)	(630.1M)
Retained Earnings	1.1B	659.4M	490.7M	416.7M	479.2M	373.6M
Accounts Payable	19.3M	11.1M	11.2M	12.1M	13.9M	9.9M
Cash	1.1B	887.0M	764.6M	669.3M	769.7M	463.4M
Non Current Assets Total	553.5M	318.0M	252.9M	206.8M	237.8M	209.9M
Cash And Short Term Investments	1.3B	1.0B	877.7M	861.5M	990.8M	557.5M
Common Stock Shares Outstanding	342.8M	351.6M	370.4M	381.0M	438.1M	233.2M
Liabilities And Stockholders Equity	1.9B	1.4B	1.2B	1.1B	1.3B	809.1M
Non Current Liabilities Total	10.7M	9.1M	3.9M	2.6M	2.9M	4.5M
Other Current Assets	12.3M	9.0M	13.6M	5.4M	6.2M	6.2M
Other Stockholder Equity	34.6M	32.5M	42.7M	48.4M	55.7M	58.5M
Total Liab	217.5M	63.5M	72.0M	44.0M	50.6M	79.6M
Total Current Assets	1.4B	1.1B	960.2M	933.3M	1.1B	599.3M
Short Long Term Debt Total	9.8M	9.8M	3.9M	2.6M	2.9M	2.8M
Other Liab	1.8M	2.2M	2.0M	1.4M	1.6M	1.5M
Net Tangible Assets	1.5B	1.5B	1.3B	1.1B	1.3B	683.9M
Property Plant And Equipment Net	197.4M	83.0M	62.8M	60.8M	69.9M	83.2M
Non Currrent Assets Other	87.7M	100K	72.5M	45K	51.8K	49.2K
Other Assets	64.4M	87.7M	80.7M	193K	222.0K	210.9K
Net Receivables	26.0M	33.3M	31.3M	35.9M	41.3M	43.3M
Good Will	179.5M	1.1M	1.0M	1.1M	1.2M	1.2M
Inventory	44.0M	32.8M	37.6M	30.5M	35.1M	23.1M
Long Term Investments	19.2M	135.2M	89.7M	54.7M	62.9M	35.9M
Property Plant And Equipment Gross	197.4M	83.0M	207.2M	200.6M	230.7M	242.2M
Accumulated Other Comprehensive Income	43.0M	49.9M	(797K)	20.7M	23.8M	15.9M
Short Term Debt	1.3M	2.7M	1.3M	994K	894.6K	849.9K
Intangible Assets	69.7M	18.1M	26.7M	21.1M	24.2M	26.0M
Common Stock	569.3M	595.5M	611.3M	613.7M	705.8M	355.3M
Property Plant Equipment	166.5M	197.4M	83.0M	62.8M	72.3M	85.3M
Capital Surpluse	23.2M	34.6M	32.5M	42.7M	49.1M	51.5M
Cash And Equivalents	1.2B	1.1B	887.0M	764.6M	879.3M	622.7M
Net Invested Capital	1.7B	1.3B	1.1B	1.1B	1.3B	1.1B

When determining whether Cronos Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cronos' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cronos Group Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cronos Group Stock:

How To Invest In Cronos

Details

Is Cronos Stock a good investment?

Details

What is Cronos' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cronos Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.

Please note, there is a significant difference between Cronos' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cronos is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cronos' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cronos Selling And Marketing Expenses vs Research Development Analysis

Selling And Marketing Expenses vs Research Development

Selling And Marketing Expenses vs Research Development Correlation Analysis

Correlation Coefficient

Selling And Marketing Expenses

Research Development

Cronos fundamental ratios Correlations

Cronos Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cronos fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Cash	+ 1.0	Total Stockholder Equity

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Retained Earnings	- 0.98	Net Debt